LONG-ACTING FORMS OF HIV PREVENTION

For some people, long-acting forms of HIV prevention may be more desirable than a daily pill.

HIV prevention today — and in the future.

Taking an oral dose of the medication Truvada once a day, every day can prevent HIV infection.

NIAID-funded researchers are developing and testing alternative HIV prevention products that could be inserted, injected, infused or implanted from:

- Polymer ring inserted into the vagina releases antiretroviral drug over time.
- Device implanted in the body releases antiretroviral drug over time.
- Long-acting antiretroviral drug is injected into the body.
- Antibody is infused or injected into the body.

NIAID is funding research on 4 types of long-acting HIV prevention.

- **INTRAVAGINAL RING (IVR)**
  - dapivirine IVR (MTN 025/HOPE and MTN 034/REACH clinical trials)
  - tenofovir IVR (CONRAD)
  - Truvada IVR (Oak Crest Institute of Science)

- **IMPLANT**
  - cabotegravir (SLAP-HIV project)
  - dolutegravir (University of North Carolina)
  - tenofovir alafenamide (Oak Crest Institute of Science)
  - tenofovir alafenamide & emtricitabine (Houston Methodist Research Institute)

- **INJECTABLE**
  - cabotegravir (HPTN 077, 083 & 084 clinical trials)
  - 10E8VLS (VRC 610 clinical trial)
  - CAP256V2LS (NIAID VRC & CAPRISA)
  - N6LS (VRC 609 clinical trial)
  - Sanofi trispecific antibody (HVTN 129/HPTN 088 clinical trial)
  - VRC01 (AMP Studies, HVN 116 & IMPAACT P1112 clinical trials)
  - VRC01LS (HV N116 & IMPAACT P1112 clinical trials)
  - VRC07-523LS (VRC 610 & HVN 127/HPTN 087 clinical trials)

- **ANTIBODY**
  - Monthly
  - Yearly

How many products are under investigation?

- Safety studies & manufacturing
- Design and development
- Human studies

For more on the latest advances in HIV prevention research, visit:

@NIAIDNews
www.niaid.nih.gov facebook.com/niaid.nih